Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions

Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions

Idiopathic pulmonary fibrosis (IPF) was considered untreatable until the development of therapeutic drugs and diagnostic technology that made it possible to slow the progression of IPF. In 2014, pirfenidone and nintedanib were approved simultaneously as therapeutic drugs for patients with IPF. These...

Full description

Bibliographic Details
Main Author:	Won-Il Choi
Format:	Article
Language:	English
Published:	Sungkyunkwan University School of Medi 2021-03-01
Series:	Precision and Future Medicine
Subjects:	idiopathic pulmonary fibrosis nintedanib pirfenidone
Online Access:	http://www.pfmjournal.org/upload/pdf/pfm-2020-00205.pdf

Similar Items

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
by: James Patrick Finnerty, et al.
Published: (2021-12-01)

Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives
by: Moua T, et al.
Published: (2019-01-01)

Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
by: Carlo Albera, et al.
Published: (2021-09-01)

Idiopathic pulmonary fibrosis: the turning point is now!
by: Manuela Funke, et al.
Published: (2015-05-01)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
by: Timothy M. Dempsey, et al.
Published: (2022-01-01)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020-10-01)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023-12-01)

Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
by: Céline Audibert, et al.
Published: (2016-08-01)

Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
by: Valeria Casillo, et al.
Published: (2019-09-01)

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
by: Ida Pesonen, et al.
Published: (2018-05-01)

Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
by: David A. Scott, et al.
Published: (2019-08-01)

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
by: Paolo Cameli, et al.
Published: (2022-08-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
by: Jia Liu, et al.
Published: (2024-04-01)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
by: Kazutaka Takehara, et al.
Published: (2022-01-01)

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
by: Paolo Cameli, et al.
Published: (2020-09-01)

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2024-02-01)

Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data
by: Mohammed Ayaz Khan, et al.
Published: (2023-01-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
by: Shih-Lung Cheng, et al.
Published: (2022-09-01)

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
by: Stefano Levra, et al.
Published: (2022-12-01)

Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease
by: Neha P. Mandovra, et al.
Published: (2023-10-01)

Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention
by: Vito D’Agnano, et al.
Published: (2024-02-01)

Comparative study between pirfenidone and traditional drugs in treatment of idiopathic pulmonary fibrosis
by: Ramadan M Nafee, et al.
Published: (2019-01-01)

Effects of Anti-Fibrotic Drugs on Transcriptome of Peripheral Blood Mononuclear Cells in Idiopathic Pulmonary Fibrosis
by: Daisuke Ishii, et al.
Published: (2024-03-01)

Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study
by: Myung Jin Song, et al.
Published: (2021-05-01)

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
by: Graney BA, et al.
Published: (2018-09-01)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
by: John N. Shumar, et al.
Published: (2021-05-01)

Lung Fibrosis after COVID-19: Treatment Prospects
by: Evgeny Bazdyrev, et al.
Published: (2021-08-01)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
by: Ryosuke Imai, et al.
Published: (2020-03-01)

Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study
by: Sergey Avdeev, et al.
Published: (2023-02-01)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
by: Tomoo Kishaba
Published: (2019-03-01)

Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review
by: Toshihiro Shiratori, et al.
Published: (2020-06-01)

Historical eye on IPF: a cohort study redefining the mortality scenario
by: Sara Tomassetti, et al.
Published: (2023-06-01)

Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
by: S. N. Avdeev, et al.
Published: (2018-10-01)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
by: Goran Nadir Salih, et al.
Published: (2016-09-01)

Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study
by: Jang Ho Lee, et al.
Published: (2023-02-01)

Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
by: V. Cottin
Published: (2012-06-01)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2017-11-01)

Drug-Induced Thrombocytopenia Due to Nintedanib during Treatment of Idiopathic Pulmonary Fibrosis
by: Igor Dumic, et al.
Published: (2023-05-01)

Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study
by: Ho Young Lee, et al.
Published: (2023-10-01)